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Abstract 
Background: Little is known about age‑specific target blood pressure (BP) in hypertensive patients with diabetes 
mellitus (DM). The aim of this study was to determine the BP level at the lowest cardiovascular risk of hypertensive 
patients with DM according to age.
Methods: Using the Korean National Health Insurance Service database, we analyzed patients without cardiovascu‑
lar disease diagnosed with both hypertension and DM from January 2002 to December 2011. Primary end‑point was 
composite cardiovascular events including cardiovascular death, myocardial infarction and stroke.
Results: Of 241,148 study patients, 35,396 had cardiovascular events during a median follow‑up period of 10 years. 
At the age of < 70 years, the risk of cardiovascular events was lower in patients with BP < 120/70 mmHg than in those 
with BP 130–139/80–89 mmHg. At the age of ≥ 70, however, there were no significant differences in the risk of cardio‑
vascular events between patients with BP 130–139/80–89 mmHg and BP < 120/70 mmHg. The risk of cardiovascular 
events was similar between patients with BP 130–139/80–89 mmHg and BP 120–129/70–79 mmHg, and it was signifi‑
cantly higher in those with BP ≥ 140/90 mmHg than in those with BP 130–139/80–89 mmHg at all ages.
Conclusions: In a cohort of hypertensive patients who had DM but no history of cardiovascular disease, 
lower BP was associated with lower risk of cardiovascular events especially at the age of < 70. However, low 
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds 
the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://crea‑
tivecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdo‑
main/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Open Access
Cardiovascular Diabetology
*Correspondence:  shpark0530@yuhs.ac; kcmd.sung@samsung.com
†Hack‑Lyoung Kim and Hyue Mee Kim contributed equally to this 
manuscript
6 Division of Cardiology, Severance Cardiovascular Hospital 
and Cardiovascular Research Institute, Yonsei University College 
of Medicine, 50‑1, Yonsei‑ro, Seodaemun‑gu, Seoul 03722, Republic 
of Korea
20 Division of Cardiology, Department of Internal Medicine, Kangbuk 
Samsung Hospital, Sungkyunkwan University School of Medicine, 29 
Saemunan‑ro, Jongno‑gu, Seoul 03181, Republic of Korea
Full list of author information is available at the end of the article
Page 2 of 12Kim et al. Cardiovasc Diabetol          (2020) 19:181 
Background
Hypertension and diabetes mellitus (DM), 2 major car-
diovascular risk factors, have emerged as major medi-
cal and public health issues globally. There has been a 
continued growth in the prevalence of hypertension 
[1] and DM [2], and both conditions are associated 
with increased risk of cardiovascular morbidity and 
mortality [3–6]. Hypertension affects approximately 
70% of patients with DM, which is twice as common 
as those without DM [7]. Importantly, the coexistence 
of hypertension and DM substantially increases in the 
risk of cardiovascular disease (CVD), and chronic kid-
ney disease [8, 9]. Two thirds of diabetic patients die 
from CVD, in which hypertension is the main cause 
of CVD [10]. Therefore, it is very important to control 
hypertension in patients with DM in order to reduce 
their cardiovascular risk and to improve prognosis.
Because blood pressure (BP) rises with age, hyper-
tension is one of the main medical problem with high 
prevalence in the elderly [11]. Even in elderly peo-
ple, the beneficial effect of BP control on the reduc-
tion in the risk of cardiovascular events has been 
suggested [12, 13], and BP control should not be 
neglected. However, elderly subjects are often frail, 
have many comorbidities, and are more vulnerable to 
the side effects of intensive BP control [14]. In clini-
cal practice, many physicians are worried about the 
side effects or complications of intensive BP lowering 
in elderly patients. Therefore, age must be considered 
when setting target BP. However, there is limited data 
regarding age-specific target BP in patients with DM. 
The 2017 American College of Cardiology/American 
Heart Association (ACC/AHA) guidelines suggested a 
target BP of 130/80 mmHg for diabetic patients at all 
ages [15]. Otherwise, in patients with DM, the Euro-
pean guidelines recommended a target BP of 130/70–
79  mmHg and 130–140/70–79  mmHg for subjects 
aged < 65 years and ≥ 65 years, respectively [16]. There 
is still insufficient evidence as to whether BP needs 
to be lowered intensively in patients with DM and 
whether the target BP should differ according to age. 
Thus, the aim of this study was to determine the BP 
level at the lowest cardiovascular risk of hypertensive 
patients with DM according to age.
Methods
Data sources
This study used a database provided by the National 
Health Insurance Services-Health Screening (NIHS-
HEALS) cohort in Korea. NHIS is a single insurance 
provider in Korea and covers 97.2% of the Korean pop-
ulation; enrollees aged 40  years or older are entitled 
to a general health screening program every 2  years. 
A database includes data regarding sociodemograph-
ics, use of inpatient and outpatient services, diagnoses, 
prescriptions, death, and health screening examination 
data (e.g., health questionnaires and laboratory tests). 
The cohort details have been previously described [17]. 
The study was approved by the Institutional Review 
Board of Kangbuk Samsung Hospital (# KBSMC 2019-
01-018). The anonymized dataset was provided to the 
researchers from the NHIS and informed consent was 
waived.
Study population and patient involvement
A total of 314,293 subjects who were diagnosed with 
both hypertension and DM from January 2002 to Decem-
ber 2011 were extracted from the NIHS-HEALS cohort. 
Subjects were considered as having hypertension if: (1) 
hypertension was diagnosed before health screening 
examination, or (2) anti-hypertensive medications were 
prescribed before. Having DM was defined if: (1) DM 
was diagnosed before health screening examination, (2) 
hypoglycemic agents were prescribed before, or (3) fast-
ing glucose ≥ 126  mg/dL. Among them, patients with 
the following were excluded: prior history of myocardial 
infarction or stroke (n = 36,712), death before second 
screening (n = 623), diagnosis of malignancy (n = 28,410), 
and unavailable data (n = 7400). Therefore, a total of 
241,148 patients were finally analyzed. Flow chart for 
study enrollment is shown in Fig. 1. Individuals were fol-
lowed up until the development of death, and the first 
occurrence of cardiovascular events, or the end of the 
study (December 2017). This research was done without 
patient involvement.
BP data
The data on BP records were extracted from the NIHS-
HEALS cohort. Considering BP variability, 2 BP records 
within 4  years were averaged. BP measured using a 
sphygmomanometer or an oscillometric device. BP 
BP < 130–139/80–89 mmHg was not associated with decreased cardiovascular risk, it may be better to keep the BP of 
130–139/80–89 mmHg at the age of ≥ 70.
Keywords: Age, Cardiovascular risk, Diabetes mellitus, Hypertension, Target blood pressure
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measurements were recommended twice at 2 min inter-
vals after 5 min of stabilization.
Cardiovascular events
The collection of information on the occurrence of car-
diovascular events began the day after second check-up, 
and patients with cardiovascular events between 2 check-
ups were excluded from the study. Baseline clinical data 
used in this study was obtained from the second check-
up. The primary study endpoint was major cardiovas-
cular events including cardiovascular death, myocardial 
infarction and stroke. A diagnosis of myocardial infarc-
tion was made based on discharge diagnosis after a hos-
pitalization (ICD-10 codes: I21-23). A diagnosis of stroke 
was made based on discharge diagnosis (ICD-10 codes: 
I60-69) in patients who had been hospitalized and under-
gone brain imaging [18]. The cause and date of death 
were confirmed by the records from the National Statis-
tical Office of Korea. The secondary study endpoint was 
each clinical event.
Statistical analysis
Continuous variables are expressed as mean (standard 
deviation) and categorical variables as percentages. The 
mean values of continuous variables were compared 
using analysis of variance, and the frequencies of categor-
ical variable were compared using chi-square test among 
BP category groups. The incidence of endpoints was 
calculated using the total number of outcomes during 
the follow-up period divided by 100,000 person-years. 
Multivariable analysis was performed using the Cox pro-
portional hazard model to evaluate the relationship of 
BP with the cardiovascular events and mortality. Haz-
ard ration (HR) and 95% confidence interval (CI) were 
calculated and adjusted for age, income level, history of 
smoking, physical activity, alcohol consumption, body 
mass index, fasting glucose, total cholesterol, and use 
of aspirin or statin. Subgroup analyses were performed 
by dividing the patients into those aged < 50  years, 
50–59  years, 60–69  years, and ≥ 70  years to determine 
the appropriate target BP according to age. Restricted 
cubic splines were fitted to evaluate the non-linear rela-
tionship between BP and outcomes. P value < 0.05 was 
considered statistically significant. Statistical analyses 
were performed using SAS Statistical Software (version 
9.4, SAS Institute, Cary, North Carolina, USA) and R Sta-
tistical Software (version 3.5.2, R Foundation for Statisti-
cal Computing, Vienna, Austria).
Results
Baseline characteristics of the study patients according 
to BP categories
The baseline characteristics of the study subjects accord-
ing to BP categories are shown in Table 1. Compared to 
the lower BP group, the higher BP group tended to be 
older and male, had higher BMI, consumed more alcohol, 
had low household income, had higher level of fasting 
glucose and total cholesterol, and more frequently used 
aspirin or antihypertensive medications, and less fre-
quently used statin.
Cardiovascular events according to BP and age categories
A total of 35,396 events occurred during a median follow-
up period of 10.0 years. Cardiovascular events according 
to BP and age categories are shown in Table 2. In the total 
population, as BP rose, cardiovascular events more fre-
quently occurred: the incidence of cardiovascular events 
was lowest in the lowest BP group (< 120/70  mmHg) 
Fig. 1 Study flowchart showing patient enrollment
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(1212/10,000 person-years), and highest in the highest BP 
group (≥ 150/100  mmHg) (2293/10,000 person-years). 
Compared to patients with BP 130–139/80–89  mmHg, 
the risk of cardiovascular events was significantly lower 
in those with BP < 120/70  mmHg and BP 120–129/70–
79  mmHg with HR of 0.85 (95% CI 0.80–0.90) and HR 
of 0.94 (95% CI 0.92–0.97), respectively. Compared to 
patients with BP 130–139/80–89 mmHg, the risk of car-
diovascular events was significantly higher in those with 
BP 140–149/90–99  mmHg and BP ≥ 150/100  mmHg 
with HR of 1.12 (95% CI 1.09–1.15) and HR of 1.33 (95% 
CI 1.29–1.37), respectively.
At the age of < 70  years, the risk of cardiovascu-
lar events was significantly lower in patients with 
BP < 120/70  mmHg than in those with BP 130–
139/80–89  mmHg. The risk reduction was stronger at 
younger ages: HRs (95% CIs) were 0.74 (0.61–0.90), 
0.87 (0.77–0.99), and 0.86 (0.78–0.95), in patients 
with < 50  years, 50–59  years, and 60–69  years, respec-
tively. At the age of ≥ 70  years, however, there were no 
significant differences in the risk of cardiovascular events 
between patients with BP 130–139/80–89  mmHg and 
BP < 120/70 mmHg with HR of 0.99 (95% CI 088–1.11). 
The risk of cardiovascular events was similar between 
patients with BP 130–139/80–89  mmHg and BP 120–
129/70–79  mmHg at all ages. The risk of cardiovas-
cular events was significantly higher in patients with 
BP ≥ 140/90  mmHg than those with BP 130–139/80–
89 mmHg at all ages. The younger the patients, the higher 
the risk. Adjusted HRs for the risk of cardiovascular 
events according to BP and age categories are also dem-
onstrated in Fig.  2. Restricted cubic spline curves show 
age-specific adjusted hazard ratios for cardiovascular 
events according to systolic BP (SBP) and diastolic BP 
Table 2 Cardiovascular events of study subjects according to BP and age categories
HR, hazard ratio; CI, confidence interval. BP, blood pressure
Clinical event  < 120/ < 70 mmHg 120–129/70–79 mmHg 130–
139/80–
89 mmHg
140–149/90–99 mmHg  ≥ 150/ ≥ 100 mmHg
Total
 Events 1123 7625 13,764 8188 4696
 Person‑years 92,622 567,439 983,762 484,528 204,774
 Incidence (events/100,000 person‑
years)
1212 1344 1399 1690 2293
 Adjusted HR (95% CI) 0.85 (0.80–0.90) 0.94 (0.92–0.97) Ref 1.12 (1.09–1.15) 1.33 (1.29–1.37)
 < 50 years
 Events 113 951 1763 874 430
 Person‑years 30,886 167,650 288,016 119,956 39,039
 Incidence (events/100,000 person‑
years)
366 567 612 729 1101
 Adjusted HR (95% CI) 0.74 (0.61–0.90) 0.96 (0.89–1.04) Ref 1.20 (1.10–1.30) 1.79 (1.61–1.99)
50–59 years
 Events 265 1860 3409 1815 877
 Person‑years 27,949 182,438 318,830 146,385 55,314
 Incidence (events/100,000 person‑
years)
948 1020 1069 1240 1585
 Adjusted HR (95% CI) 0.87 (0.77–0.99) 0.94 (0.89–1.00) Ref 1.16 (1.10–1.23) 1.43 (1.32–1.54)
60–69 years
 Events 425 2999 5361 3301 1916
 Person‑years 24,115 158,546 276,831 155,068 72,302
 Incidence (events/100,000 person‑
years)
1762 1892 1937 2129 2650
 Adjusted HR (95% CI) 0.86 (0.78–0.95) 0.97 (0.92–1.01) Ref 1.09 (1.05–1.14) 1.32 (1.25–1.39)
 ≥ 70 years
 Events 320 1815 3231 2198 1473
 Person‑years 9670 58,803 100,083 63,116 38,117
 Incidence (events/100,000 person‑
years)
3309 3087 3228 3482 3864
 Adjusted HR (95% CI) 0.99 (0.88–1.11) 0.95 (0.89–1.00) Ref 1.08 (1.03–1.14) 1.17 (1.10–1.25)
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(DBP) categories (Fig. 3). There was a significant interac-
tion between SBP and age for the prediction of cardiovas-
cular events (interaction P < 0.001).
Similar results were obtained in sex-specific 
analysis (Additional file  1: Tables S1 and S2). Low 
BP < 120/70  mmHg was more associated with reduced 
cardiovascular risk in women than in men. The inci-
dence of cardiovascular events with high BP above 130–
139/80–89  mmHg was consistently observed regardless 
of obesity (Additional file 1: Tables S3 and S4). All-cause 
mortality and primary end-point results according to 
BP and age categories are demonstrated in Additional 
file  1: Tables S5–S8. The risk of all-cause or cardiovas-
cular mortality was significantly higher in patients with 
BP < 120/70  mmHg than in those with BP 130–139/80–
89 mmHg in patients with age of ≥ 60 years. The risk of 
myocardial infarction was not different between patients 
with BP < 120/70 mmHg and BP 130–139/80–89 mmHg 
Fig. 2 Adjusted hazard ratio for the risk of cardiovascular events according to blood pressure and age categories
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at all ages. However, the risk of stroke was significantly 
lower in patients with BP < 120/70 mmHg than in those 
with BP 130–139/80–89 mmHg at all ages. All-cause or 
cardiovascular mortality and the risk of stroke were sig-
nificantly higher in patients with BP > 140/90 mmHg than 
in those with BP 130–139/80–89 mmHg at all ages. The 
risk of myocardial infarction was significantly increased 
when BP was ≥ 150/90 mmHg.
Cardiovascular risks in patients with anti‑hypertensive 
medications
A total of 105,572 (43.8%) patients were taking anti-
hypertensive medications. In these patients with anti-
hypertensive medications, the risk of cardiovascular 
events was not different among those with BP < 120/70, 
120–129/70–79, and 130–139/80–89 mmHg, and it was 
significantly higher in patients with BP ≥ 140/90  mmHg 
than in those with BP 130–139/80–89 mmHg at the age 
of < 70  years. At the age of ≥ 70  years, the risk of car-
diovascular events was not different among patients 
with BP < 120/70, 120–129/70–79, 130–139/80–89, and 
140–149/90–99  mmHg, and it was significantly higher 
in those with BP ≥ 150/100  mmHg than in those with 
BP 130–139/80–89  mmHg (Table  3). All-cause and 
cardiovascular mortality tended to increase in those with 
BP < 120/70  mmHg, compared to those with BP 130–
139/80–89 mmHg at all ages (Additional file 1: Tables S9 
and S10). At BP ≥ 150/100 mmHg, the risk of myocardial 
infarction tended to increase, but the differences were 
not statistically significant either age (Additional file  1: 
Table S11). The lower the blood pressure, the lower the 
risk of stroke at all ages (Additional file 1: Table S12).
Discussion
In this nationwide population-based cohort of 241,148 
patients with both hypertension and DM, but without 
CVD, those with BP < 120/70  mmHg had significantly 
lower risk of cardiovascular events than those with BP 
130–139/80–89  mmHg at the age of < 70  years. How-
ever, there was no significant difference in the risk of car-
diovascular events in patients with BP < 120/70  mmHg 
and BP 130–139/80–89  mmHg at the age ≥ 70. For 
patients on anti-hypertensive medications, the risk of 
cardiovascular events was similar between patients with 
BP ≤ 130–139/80–89  mmHg and higher in those with 
BP ≥ 140/90 mmHg at all ages. These results suggest that 
optimal target BP in patients with DM may differ accord-
ing to age and that: lowering BP to < 130/80 mmHg may 
Fig. 3 Restricted cubic spline curves showing age‑specific adjusted hazard ratios for the risk of cardiovascular events according to SBP and DBP 
categories. Solid lines indicate hazard ratios and shaded areas indicate 95% confidence intervals. SBP, systolic blood pressure; DBP, diastolic blood 
pressure
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be effective at the age of < 70 years, but not in those at the 
age of ≥ 70  years. In addition, the lower the better may 
not be applied in patients on anti-hypertensive medi-
cations, because all-cause or cardiovascular mortality 
tended to be even higher in those with < 120/70 mmHg. 
Based on these results, the drug goal should be less than 
140/90 mmHg but individualized.
Although high prevalence of hypertension in patients 
with DM [7], and markedly increased risk of cardiovas-
cular events in coexistence of hypertension and DM [8, 
9], there is limited data on optimal target BP in patients 
with DM. In a large randomized controlled trial (RCT) 
of patients with DM demonstrated that lowering SBP 
to < 135  mmHg using perindopril and indapamide regi-
men was shown to be significantly associated with 
reductions in cardiovascular events, compared to the pla-
cebo group whose SBP was maintained at ~ 140  mmHg 
[19]. However, another RCT showed that, compared 
with ~ 135  mmHg, an achieved SBP to 121  mmHg did 
not reduce cardiovascular morbidity and mortality in 
patients with DM [20]. Meta-analyses confirmed that 
reduction of SBP of < 140 mmHg is associated with better 
cardiovascular outcomes [21], but there is no beneficial 
effect when SBP is lowered to < 130  mmHg in patients 
with DM [22]. Another meta-analysis of 73,914 subjects 
with DM reported that lowering SBP to < 130  mmHg 
recued stroke by 39%; however, there was no risk reduc-
tion in myocardial infarction [23]. Excluding the effect 
of strong glycemic control in diabetic patients, a more 
intensive lowering SBP to < 130  mmHg improved over-
all outcomes [24]. On the line of similar results, recent 
meta-analyses showed that in diabetic patients, if the 
baseline SBP ≥ 140  mmHg, antihypertensive treatment 
reduced cardiovascular risk; however, if the baseline 
Table 3 Cardiovascular events of study subjects with anti-hypertensive medications according to BP and age categories
HR, hazard ratio; CI, confidence interval. BP, blood pressure
Clinical event  < 120/ < 70 mmHg 120–129/70–79 mmHg 130–
139/80–
89 mmHg
140–149/90–99 mmHg  ≥ 150/ ≥ 100 mmHg
Total
 Events 397 2901 5606 3519 2145
 Person‑years 25,355 195,990 389,630 20,951 97,809
 Incidence (events/100,000 person‑
years)
1566 1480 1439 16,796 2193
 Adjusted HR (95% CI) 0.95 (0.85–1.05) 0.97 (0.93–1.02) Ref 1.11 (1.06–1.16) 1.29 (1.23–1.36)
 < 50 years
 Events 21 214 511 269 136
 Person‑years 3985 35,306 80,961 38,353 13,671
 Incidence (events/100,000 person‑
years)
527 606 631 701 995
 Adjusted HR (95% CI) 0.89 (0.57–1.38) 0.97 (0.82–1.14) Ref 1.11 (0.95–1.28) 1.58 (1.30–1.91)
50–59 years
 Events 78 586 1285 738 342
 Person‑years 7829 63,159 127,672 62,997 25,614
 Incidence (events/100,000 person‑
years)
996 928 1006 1171 1335
 Adjusted HR (95% CI) 0.97 (0.77–1.22) 0.91 (0.82–1.00) Ref 1.16 (1.06–1.27) 1.28 (1.13–1.44)
60–69 years
 Events 151 1255 2231 1450 928
 Person‑years 8827 68,351 128,304 74,550 37,595
 Incidence (events/100,000 person‑
years)
1711 1836 1739 1945 2468
 Adjusted HR (95% CI) 0.95 (0.80–1.12) 1.05 (0.98–1.13) Ref 1.10 (1.03–1.18) 1.37 (1.27–1.48)
≥ 70 years
 Events 147 846 1579 1062 739
 Person‑years 4713 29,172 52,691 33,611 20,927
 Incidence (events/100,000 person‑
years)
3119 2900 2997 3160 3531
 Adjusted HR (95% CI) 1.00 (0.85–1.19) 0.95 (0.87–1.03) Ref 1.05 (0.97–1.14) 1.15 (1.05–1.25)
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SBP < 140  mmHg, there was no observed benefit in BP 
lowering therapy [25, 26]. As mentioned above, each 
study has different target BP, and the results are slightly 
different, making it difficult to clarify where to put the 
target BP in patients with DM. In a whole study popu-
lation in our study, the lower the BP, the lower the car-
diovascular events, and thus, the target BP of DM may be 
suggested as < 130/80 mmHg, if we do not consider age. 
Most of the existing studies, including meta-analysis, 
were conducted in the West, but this study is an Asian 
study, and racial differences should be considered when 
interpreting our results.
However, age should be considered when setting target 
BP in hypertensive subjects. Although lowering BP obvi-
ously improves clinical outcome [12, 13], adverse effects 
more frequently occur with intensive treatment in older 
people [14, 27]. There is still no standard guideline for tar-
get BP in elderly subjects. The 2 most widely used guide-
lines show somewhat differences in target BP in older 
people. The 2017 ACC/AHA guideline recommends a 
target BP of < 130/80  mmHg in the elderly, which is the 
same in younger age [15]. However, there is disagree-
ment with setting the same target BP (< 130/80 mmHg) 
in subjects aged 30 and 80  years [27]. Indeed, lowering 
BP to < 130/80 mmHg is difficult in some elderly subjects, 
especially when they have isolated systolic hypertension 
and poor vascular compliance [27]. Also, there is concern 
about more frequent and serious adverse effects from 
intensive BP control in more frail older subjects [13]. In 
this context, the 2018 European Society of Cardiology/
European Society of Hypertension (ESC/ESH) guide-
line recommended that in older subjects on BP-lowering 
drugs, BP should be lowered to < 140/80 mmHg, but not 
SBP < 130 mmHg [16]. Although age is an important fac-
tor for hypertension control, there have been few studies 
on whether age should be considered when setting target 
BP in subjects with DM. In the present study, the risk of 
cardiovascular events was not different among patients 
with BP < 120/70, 120–129/70–79 and 130–139/80–
89 mmHg at the age of ≥ 70 years, suggesting that older 
subjects with DM do not need strict BP control, which is 
in line with 2018 ESC/ESH guideline [16]. For patients on 
anti-hypertensive medications, our study showed that the 
risk of cardiovascular events was similar in all patients 
with BP ≤ 130–139/80–89  mmHg and higher in those 
with BP ≥ 140/90 mmHg, at all ages. Rather, when BP was 
lowered to < 130/80  mmHg, all-cause or cardiovascular 
mortality tended to rise at all ages. These results suggest-
ing different target BPs according to age and anti-hyper-
tensive medications in diabetic patients deserve attention 
and could be of clinical use.
The results of the present study showed that the risk 
of cardiovascular events associated with elevated BP 
decreased as patients became older: reduction in BP 
from 130–139/80–89 to < 120/70  mmHg was associ-
ated 26% reduction in the risk of cardiovascular events 
at the age of < 50  years, as low as 13% ~ 14% at the 
age of 50–69  years, and no beneficial effect at the age 
of ≥ 70 years. These results are in line with those of previ-
ous studies in the general population [28]. In the elderly, 
irreversible pathological changes in vasculature caused 
by long-standing high BP may develop and lead to car-
diovascular events despite a lowered, even normalized 
BP [27]. The effective prevention of cardiovascular events 
can be expected by lowering BP in younger patients with 
DM, so that they need more strict BP control.
Our results suggest that BP can be safely lowered 
to < 130/80  mmHg in younger patients with DM, but 
not in elderly diabetics aged ≥ 70  years. However, cur-
rent study analyzed diabetic patients who were relatively 
healthy, had no history of CVD and received regular 
health check-ups. In high-risk diabetics with a history 
of CVD, the target BP of < 130/80  mmHg may be more 
appropriate even at the age of ≥ 70 years [29, 30]. Other-
wise, target BP should not be lowered to < 130/80 mmHg 
in diabetic patients with comorbidities and high frailty 
even at the age of < 70 years due to the risk of side effects 
of intensive BP lowering [31]. Target BP should be indi-
vidualized according to the risk of cardiovascular events, 
comorbidities, frailty and age [32]. In addition, the lower 
the better is not applied in patients on anti-hypertensive 
medications: at BP < 140/90 mmHg, there were no differ-
ences in the risk of cardiovascular events, but all-cause 
and cardiovascular mortality was significantly increased 
at BP < 120/70 mmHg at all ages. Based on these results, 
the target goal of anti-hypertensive medications should 
be BP < 140/90 mmHg, but not BP < 120/70 mmHg.
Limitations
Besides inherent shortcomings of the use of administra-
tive database and retrospective design, there are several 
limitations to this study. First, as the diagnosis of hyper-
tension in our study was based on the diagnostic code, 
not on the BP levels, there are several possible reasons 
why many patients diagnosed with hypertension had 
relatively normal or even low BP, even though many 
patients were not taking anti-hypertensive medications, 
as follows: (1) there might be coding errors which have 
always been an issue when using claim data. Neverthe-
less, it is reported that the diagnosis accuracy of hyper-
tension is relatively high in claim data (sensitivity = 73% 
and positive predictive value = 82%) [33], (2) patients 
who were prescribed anti-hypertensive medications 
along with health check-ups at regular basis were clas-
sified as those who take anti-hypertensive medications 
in the current study. Thus, it was possible that some 
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patients who were prescribed anti-hypertensive medi-
cations on an irregular basis or who did not undergo 
health check-ups would be miss-classified as that they 
were not taking anti-hypertensive medications even 
though they were consistently taking the medications, 
and (3) we used average value of two would be lower 
than expected. Despite the various shortcomings, claim 
data has a strength in that it is not limited to a specific 
doctors or specific medical institutions, and there is no 
selection bias. In addition, only patients taking anti-
hypertensive medications (they might be certain to be 
hypertensive) were analyzed separately, and we showed 
the same results as all patients. Second, as clinic BP 
measurements were made for the analysis, BP values 
might be less accurate. BP values from out-of-office BP 
monitoring such as ambulatory blood pressure moni-
toring or home blood pressure monitoring may provide 
more valuable information [34]. In order to minimize 
errors and inaccuracies, we averaged 2 measurements 
of BP. Third, the side effects of lowering BP were not 
identified in this study. Fourth, as the results of our 
study were obtained from relatively healthy diabetic 
patients without CVD, it should be noted that it is dif-
ficult to apply our results directly to high-risk patients 
with CVD or those with comorbidity and high frailty 
[29, 31]. Fifth, we need to be careful when interpret-
ing the results for the secondary study endpoint of the 
study. In the analysis of each clinical event (the second-
ary study endpoint, represented in Additional file  1), 
the incidence of clinical event in each group was very 
low, so the statistical power would have been weak-
ened. Sixth, information on anti-diabetic medications 
was not available in our study, because some impor-
tant anti-diabetic drugs such as dipeptidyl peptidase-4 
inhibitors and sodium-glucose co-transporter-2 inhibi-
tors were introduced into the domestic market after 
patients’ enrollment. Lastly, our results were obtained 
from all Korean patients, so that its application to other 
ethnic groups may be limited.
Conclusion
In a cohort of hypertensive patients who had DM 
but no history of CVD, lower BP was associated with 
lower risk of cardiovascular events especially at the age 
of < 70 years. Effort to lower BP of < 130/80 mmHg may 
be justified in patients at the age of < 70  years; how-
ever, the intensive BP lowering strategy is less benefi-
cial in those at the age of ≥ 70  years, and lowering BP 
to 130–139/80–89 mmHg would be appropriate at the 
age of ≥ 70. In patients on anti-hypertensive medica-
tions, target BP should be < 140/90  mmHg, but not 
BP < 120/70  mmHg. Well-designed prospective studies 
are needed to verify our findings.
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